Napredna pretraga

Pregled bibliografske jedinice broj: 1022444

Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16- positive oropharyngeal cancer: an updated meta- analysis including trials RTOG 1016 and De- ESCALaTE


Suton, Petar; Skelin, Marko; Rakušić, Zoran; Dokuzović, Stjepan; Lukšić, Ivica Lukšić
Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16- positive oropharyngeal cancer: an updated meta- analysis including trials RTOG 1016 and De- ESCALaTE // European Archives of Oto-Rhino-Laryngology, 276 (2019), 5; 1275-1281 doi:10.1007/s00405-019-05387-8 (međunarodna recenzija, članak, znanstveni)


Naslov
Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16- positive oropharyngeal cancer: an updated meta- analysis including trials RTOG 1016 and De- ESCALaTE

Autori
Suton, Petar ; Skelin, Marko ; Rakušić, Zoran ; Dokuzović, Stjepan ; Lukšić, Ivica Lukšić

Izvornik
European Archives of Oto-Rhino-Laryngology (0937-4477) 276 (2019), 5; 1275-1281

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Oropharyngeal cancer ; Human papilloma virus ; Cisplatin ; Cetuximab ; Survival ; Recurrence

Sažetak
Abstract Purpose: Human papilloma virus (HPV)- associated oropharyngeal cancer (OPC) is a special entity among head and necksquamous cell carcinomas (HNSCCs). Given its favorable prognosis, one of the de-escalating strategies in the treatment of OPC includes the introduction of cetuximab (C225) instead of cisplatin (CDDP) in conjunction with radiotherapy. An updated meta- analysis of published studies has been performed, which directly compared the efficacy of CDDP vs. C225 given concurrently with radiotherapy as definitive treatment of p16- positive OPC. Methods: A systematic literature search was performed for studies published between 2006 and 2018. A total of 1490 citations were obtained and 8 studies met inclusion criteria, with a total of 1665 patients. Results: The data from seven studies were available for the analysis of 2-year overall survival (OS). Calculated pooled OR for CDDP- based chemoradiotherapy vs. C225-based bioradiotherapy, was 0.45 (P < 0.0001). The data from eight studies were available for the analysis of 2-year locoregional recurrence (LRR). Calculated pooled OR for CDDP-based chemoradiotherapy vs. C225-based bioradiotherapy was 0.35 (P < 0.0001). Patients receiving CDDP with irradiation had 2.2- and 2.9-fold decreased risk for death from any cause and LRR, respectively. Conclusions: For patients with HPV-positive OPC, radiotherapy plus C225 showed inferior OS and higher LRR rates compared with radiotherapy plus CDDP. CDDP-based chemoradiotherapy should remain standard of definitive treatment of p16- positive OPC.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Klinika za tumore,
Opća bolnica Šibenik,
Klinička bolnica "Dubrava"

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati